Key result
Benzyl diffractate derivatives exhibit pronounced in vitro antiviral activity against RSV strain A2.
Answers are grounded in this paper and cite their sources.
Newly synthesized benzyl diffractate derivatives demonstrate promising in vitro antiviral activity against respiratory syncytial virus.
We report a two-step synthesis of benzyl diffractate ethers through the preparation of intermediate benzyl diffractate ethers with an alkyl substituent containing a terminal bromine atom. A series of new diffractaic acid based ethers are synthesized by replacing the bromine atom with various N- and S-nucleophiles. It is shown that benzyl diffractate derivatives exhibit pronounced antiviral in vitro activity against the strain A2 respiratory syncytial virus in a low micromolar concentration range. The dependence of the antiviral activity and cytotoxicity on the compound structure is determined. The analysis of biological activity data revealed two compounds of the active antiviral agents category with the selectivity indices 11.0 and 31.3.
No takes yet. Share an insight, caveat, or question.
Filimonov et al. (2024) studied Respiratory syncytial virus (RSV) infection. Benzyl diffractate derivatives was evaluated on Antiviral in vitro activity against strain A2 RSV and cytotoxicity. Benzyl diffractate derivatives exhibited pronounced in vitro antiviral activity against the strain A2 respiratory syncytial virus, with two compounds showing selectivity indices of 11.0 and 31.3.
Synapse has enriched 10 related papers. Consider them for comparative context: